Healthcare Industry News: HSMN NewsFeed
News Release - September 15, 2017
SCA Pharmaceuticals Appoints Milton Boyer as Chief Executive OfficerBoyer Brings More Than 25 Years of Experience in the Chemical and Pharmaceutical Industry
LITTLE ROCK, Ark., Sept. 15, 2017 -- (Healthcare Sales & Marketing Network) -- SCA Pharmaceuticals (SCA), a leading sterile outsourcing facility specializing in preparing customized pharmaceuticals for hospitals, pharmacies and healthcare facilities nationwide, is pleased to announce the appointment of Milton Boyer as Chief Executive Officer. Mr. Boyer, a veteran in the pharmaceutical industry, will succeed Dr. Gene Graves, SCA's founder, who announced his retirement on September 6th. Mr. Boyer will also serve on the Board of Directors for SCA Pharmaceuticals.
SCA was founded in 2010 and over the past seven years has become a nationally recognized FDA 503B outsourcing facility specializing in providing the highest quality sterile admixture services and pre-filled oral syringes to hospital pharmacies. SCA provides these services across all therapeutic areas of pharmacy including critical care, labor and delivery, anesthesia, and pain management and maintains a wide portfolio of products, including unit dosed oral syringes and drug shortage medications. Under Mr. Boyer's leadership, the company will continue its rapid growth with the opening of a new 90,000-square-foot sterile manufacturing facility in Windsor, CT this fall.
Mr. Boyer has served in technical, commercial and executive roles in the pharmaceutical industry for more than 25 years with a specific focus in contract manufacturing for both drug substance and sterile drug product. For the last decade, he has been involved in sterile drug product manufacturing, most recently as the Senior Vice President of Drug Product Manufacturing at AMRI, a global contract research and manufacturing organization. Mr. Boyer joined AMRI in 2014 upon AMRI's acquisition of Oso BioPharmaceuticals, where he served as President and CEO and as a member of the Board of Directors.
Active in trade groups and educational institutions that support the pharmaceutical and biopharmaceutical industry, Mr. Boyer serves on the board of directors of the Drug, Chemical & Allied Trades Association (DCAT) and is now on the executive committee as its President. He has also served on the external advisory board for the University of New Mexico's chemistry and biology department and been an active member of other professional organizations, including the American Association of Pharmaceutical Scientists, the Parenteral Drug Association and the Society of Chemical Manufacturers and Affiliates. Mr. Boyer has a bachelor's in chemistry/physics and a master's in biochemistry from Hardin-Simmons University and Texas Tech University.
"I am excited to join SCA at an important phase of the company's development," said Mr. Boyer. "I look forward to building on the growth that the company has experienced over the past seven years and working with SCA's talented team to continue providing the highest quality products and services to our customers. I appreciate the support and guidance provided by Dr. Graves in this transition and the opportunity to execute the company's vision."
"I am proud of all that SCA has accomplished over the past seven years and confident that the company is well-positioned for continued success under Milton's leadership," said Gene Graves, Founder and retiring CEO of SCA. "Milton brings nearly three decades of experience in the chemical and pharmaceutical industries and his expertise in sterile manufacturing is a perfect fit for the changing landscape of the 503b industry. We are confident that he is the right person to lead SCA."
About SCA Pharmaceuticals
SCA Pharmaceuticals is a nationally recognized FDA 503B outsourcing facility specializing in providing the highest quality sterile admixture services to hospital pharmacies throughout the U.S. Choosing to outsource products with SCA alleviates common problems health care facilities face such as wasted product, drug shortages, time-consuming processes, compliance issues, staffing costs, and patient safety concerns. Our state of the art facilities exceeds USP <797> standards and meets cGMP requirements. Our very talented, experienced, and dedicated team of professionals is committed to providing the safest products for patients and outstanding service. It is our policy to create a partnership with our customers based on values, quality, innovations, and patient safety. SCA has partnered with the state of Connecticut and will be one of the areas fastest growing businesses adding 360 new jobs in the next 4 years.
Source: SCA Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.